Jin Yang, Yan-Cheng Yu, Zi-Xuan Wang, Qing-Qing Li, Ning Ding, Xue-Jiao Leng, Jiao Cai, Meng-Yuan Zhang, Jing-Jing Wang, Yun Zhou, Tian-Hua Wei, Xin Xue, Wei-Chen Dai, Shan-Liang Sun, Ye Yang, Nian-Guang Li, Zhi-Hao Shi
Multiple myeloma (MM), a cancer of plasma cells, is the second most common hematological malignancy which is characterized by aberrant plasma cells infiltration in the bone marrow and complex heterogeneous cytogenetic abnormalities. Over the past two decades, novel treatment strategies such as proteasome inhibitors, immunomodulators, and monoclonal antibodies have significantly improved the relative survival rate of MM patients. However, the development of drug resistance results in the majority of MM patients suffering from relapse, limited treatment options and uncontrolled disease progression after relapse...
April 20, 2024: European Journal of Medicinal Chemistry